Tirzepatide Shows Unprecedented Weight Loss and Reduced Insulin Demand in Adults with Type 1 Diabetes and Obesity
A Phase 2 trial demonstrates that tirzepatide significantly reduces body weight, HbA1c, and total daily insulin requirements in adults with type 1 diabetes and obesity, offering a promising therapeutic strategy for managing metabolic health in this population.





